Abbott, Biogen Idec announce additional results from daclizumab HYP Phase 2b trial for RRMS Today Biogen Idec and Abbott announced additional outcomes from the SELECT Phase 2b trial, the first of two registrational studies made to evaluate the investigational substance daclizumab high-yield process in people with relapsing-remitting multiple sclerosis . Outcomes showed that DAC HYP, administered once every a month subcutaneously, met the trial’s principal endpoint by considerably reducing the annualized relapse price by 54 % in the 150 mg dose group and 50 % in the 300 mg dose group>th Joint Triennial Congress of the European and Americas Committees on Treatment and Study in Multiple Sclerosis in Amsterdam.D., Biogen Idec’s Senior Vice President of Advancement.Tissue-bound antibodies were eluted with the use of 0.1 M glycine, pH 2.8 and 2.2, after homogenization in TRIS-buffered saline with protease inhibitors. Bound antibodies were eluted with 6 M urea in 50 mM sodium citrate diluted with TRIS-buffered saline and concentrated with the use of ultrafiltration. Immunoassays Immunoassays of NC1 domains or chimeras were performed with the use of indirect and inhibition enzyme-linked immunosorbent assays. A P worth of less than 0.05 was considered to indicate statistical significance. Results Clinical Data For this retrospective study, we included serum samples from 57 sufferers with Goodpasture’s disease. The median age group of the patients at the time of medical diagnosis was 59 years ; 44 percent of most patients were women.